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Bone morphogenetic protein signaling is required
for RAD51-mediated maintenance of genome
integrity in vascular endothelial cells
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The integrity of blood vessels is fundamental to vascular homeostasis. Inactivating mutations
in the bone morphogenetic protein (BMP) receptor type II (BMPR2) gene cause hereditary
vascular disorders, including pulmonary arterial hypertension and hereditary hemorrhagic
telangiectasia, suggesting that BMPR2 and its downstream signaling pathway are pivotal to
the maintenance of vascular integrity through an unknown molecular mechanism. Here we
report that inactivation of BMPR2 in pulmonary vascular endothelial cells results in a deficit of
RAD51, an enzyme essential for DNA repair and replication. Loss of RAD51, which causes
DNA damage and cell death, is also detected in animal models and human patients with
pulmonary arterial hypertension. Restoration of BMPR2 or activation of the BMP signaling
pathway rescues RAD51 and prevents DNA damage. This is an unexpected role of BMP
signaling in preventing the accumulation of DNA damage and the concomitant loss of
endothelial integrity and vascular remodeling associated with vascular disorders.
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Bone morphogenetic proteins (BMPs) are members of thetransforming growth factor-β superfamily of cytokines;they have pleiotropic activities, including regulation of cell
proliferation, differentiation, and survival during embryogenic
development and in adult tissues1. Bone morphogenetic protein
signaling is mediated by heteromeric serine/threonine kinases
named BMP type I and type II receptors1. In complex with type I
BMP receptors, BMP receptor type II (BMPR2) plays an essential
role in development and in maintenance of vascular home-
ostasis2. Loss-of-function mutations in the BMPR2 gene cause
severe vascular diseases, such as pulmonary arterial hypertension
and, in rare cases, hereditary hemorrhagic telangiectasia3,4. Pul-
monary arterial hypertension is a serious pulmonary vascular
condition with no cure and 5-year survival rate of ~65.4%5. The
disease is characterized by sustained elevation of vascular resis-
tance in distal pulmonary arteries and increased pulmonary
artery pressure, leading to right ventricular heart failure5. Up to
75% of patients with a family history of pulmonary arterial
hypertension and ~20% of patients with sporadic idiopathic
pulmonary arterial hypertension carry a loss-of-function muta-
tion in the BMPR2 gene6. Even pulmonary arterial hypertension
patients without BMPR2 mutations often exhibit a reduced
expression of BMPR27. Despite the causal link between pul-
monary arterial hypertension and impairment of
BMPR2 signaling6, the molecular etiology of pulmonary arterial
hypertension remains incompletely understood. For example, in
addition to genetic causes, exposure to drugs such as ampheta-
mines, anorexigens, and chemotherapeutic agents can trigger
pulmonary arterial hypertension, albeit rarely8–10.
Normal pulmonary vascular homeostasis is maintained by a
balance between vascular repair and injury induced by various
factors, such as shear stress, oxidative stress, and cellular meta-
bolic products, including reactive oxidative species, inflammatory
cytokines, and environmental toxins11. Endothelial cells, which
line the interior surface of blood vessels in a single layer, are
directly exposed to these harmful factors and are prone to injury
and subsequent repair. When endothelial cells are damaged,
endothelial integrity depends on the extent of the damage and the
endothelial cell capacity to repair the damage11. Unrepaired DNA
damage results in genetic mutations, recombination, premature
apoptosis, and chromosomal aberrations12. Interestingly, endo-
thelial cells derived from the vascular lesions of pulmonary
arterial hypertension patients have been shown to be hyper-
proliferative, apoptosis resistant, and genetically unstable, with
microsatellite instability and mutations in genes controlling
proliferation and apoptosis13. Likewise, somatic genomic
abnormalities have been identified in the vascular lesions of
pulmonary arterial hypertension patients and endothelial cells
from the pulmonary arteries of pulmonary arterial hypertension
patients show severe somatic chromosomal abnormalities14.
However, it is still uncertain whether genomic instability precedes
and causes the development of pulmonary arterial hypertension,
which occurs through a process that can span three to five dec-
ades. Furthermore, it remains unclear whether the impairment of
bone morphogenetic protein/BMPR2 signaling is involved in the
susceptibility to genomic instability.
DNA double-strand breaks are considered highly damaging in
many tissues, including endothelial cells, and require prompt and
accurate repair15. Homologous recombination is the primary
mechanism involved in DNA double-strand break repair16,17.
RAD51 is an essential factor in DNA double-strand break repair,
acting through gene conversion18 and participating in sister
chromatin exchange in mammalian cells18. Upon genotoxic
stress, RAD51 is recruited to DNA damage sites where it mediates
the search for a homologous sequence during homologous
recombination19. RAD51 also plays a critical role in stabilizing
the DNA replication fork by promoting survival of replication
stress and preventing accumulation of replication-associated
DNA double-strand breaks20. Loss-of-function mutations or
reduction of RAD51 lead to deregulation of homologous
recombination, which results in increased sensitivity to DNA
damaging agents and increased genetic rearrangements21, sug-
gesting that cellular RAD51 is regulated to ensure proper
execution of homologous recombination and the maintenance of
genome integrity22. It has been reported that endothelial cells
from pulmonary arterial hypertension patients and pulmonary
microvascular endothelial cells with reduced BMPR2 protein are
more sensitive to DNA damage due to decreased amounts of
BRCA1 and DNA Topoisomerase II binding protein 1, both of
which have critical roles in relaying the DNA damage signal23,24.
In this study, we show that the depletion or inhibition of
BMPR2 activity leads to a decrease of RAD51 and an increase of
DNA damage. Both can be rescued by stimulation with BMP9.
We demonstrate that loss-of-function mutations in BMPR2 result
in genome instability and mutations, which contribute to the
development of pulmonary vascular lesions through RAD51
deficiency.
Results
Loss of BMPR2 leads to depletion of RAD51. An attenuation of
BRCA1 can be detected both in human primary pulmonary
microvascular endothelial cells in which BMPR2 has been
downregulated and in endothelium from idiopathic pulmonary
arterial hypertension patients, indicating a link between dereg-
ulation of the BMPR2 signaling pathway and the level of
BRCA123. As BRCA1 is known to activate RAD51 and promote
homologous recombination—a relatively error-free DNA damage
response mechanism16,25—we hypothesized that decrease or loss
of BMPR2 leads to deregulation of the homologous recombina-
tion repair mechanism through decreased RAD51. By transfect-
ing small interfering RNA (siRNA) against BMPR2 (si-BMPR2)
into human pulmonary microvascular endothelial cells, we con-
firmed a 98% reduction of BMPR2 messenger RNA (mRNA; P=
0.0032) and an ~70% reduction of BMPR2 protein (P= 0.0035)
using quantitative PCR and immunoblotting (Fig. 1a, b). The
reduced BMPR2 amount correlated with a 72.8% reduction of
BRCA1 mRNA (P= 0.0172, Fig. 1a), consistent with previous
results23. Given the established link between BRCA1 and
RAD5125, we investigated the role and function of RAD51 in
pulmonary microvascular endothelial cells upon downregulation
of BMPR2. At 48 h after transfection of si-BMPR2, pulmonary
microvascular endothelial cells showed a 71% reduction of
RAD51 mRNA (P= 0.042, Fig. 1a) and a 60.7% reduction of
RAD51 protein (P= 0.0101, Fig. 1b) compared to pulmonary
microvascular endothelial cells transfected with non-targeting
control siRNA (Fig 1a, b). Similarly, when si-BRCA1 was trans-
fected into pulmonary microvascular endothelial cells and the
level of BRCA1 mRNA was reduced by 94.6% (P= 0.0005,
Fig. 1c), RAD51 mRNA and protein were reduced to 48% (P=
0.0204, Fig. 1c) and 73% (P= 0.0055, Fig. 1d), respectively,
compared to control pulmonary microvascular endothelial cells.
These results suggest that reduced BMPR2 in pulmonary
microvascular endothelial cells can lead to decreased RAD51.
Thus, we examined the extent of DNA damage as a result of the
decrease in RAD51 using the alkaline single-cell gel electro-
phoresis assay (hereafter referred to as alkaline comet assay),
which detects single-strand breaks, double-strand breaks, and
alkaline-labile sites in DNA26. Si-BMPR2-transfected pulmonary
microvascular endothelial cells showed a 61% higher level of
fragmented DNA that could be electrophoresed away from nuclei
(tail DNA), a sign of DNA damage, compared to control
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Fig. 1 Ablation of BMPR2 results in a reduction of RAD51 and promotes DNA damage. a The amount of BMPR2, BRCA1, and RAD51 mRNA relative to
GAPDH mRNA was measured 48 h after control (Con) or BMPR2 siRNA transfection initiations using quantitative PCR analysis (n= 3). b The amount of
RAD51, BMPR2, and GAPDH (loading control) protein in Con or BMPR2 siRNA-transfected pulmonary microvascular endothelial cells (PMVECs). GAPDH
was used for normalization. Representative image and the quantitations of three independent experiments are shown (n= 3). c The level of BRCA1 and
RAD51 mRNA relative to GAPDH mRNA in Con or BRCA1 siRNA-transfected PMVECs (n= 3). d RAD51 and GAPDH (loading control) protein amount in
Con or BRCA1 siRNA-transfected PMVECs were analyzed. Representative image and the quantitation of three independent experiments are shown (n= 3).
e DNA damage of control (Con) or BMPR2 siRNA-transfected PMVECs were analyzed 48 h after siRNA transfection initiation using alkaline single-cell gel
electrophoresis (alkaline comet assay). The fraction (%) of cells with DNA damage (arrow heads) was analyzed by ImageJ software. Representative
images of alkaline comet assay and the quantitation of 116–204 cells are shown. f p53 protein amount (n= 3) and g p21mRNA expression (n= 3) in Con or
BMPR2 siRNA-transfected PMVECs was examined. GAPDH was used for normalization. Bars represent mean ± SEM from three different experiments per
conditions in (a–g). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus respective control. Unpaired two-tailed t-test was used in (a–g)
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siRNA-transfected pulmonary microvascular endothelial cells (P
< 0.0001, Fig. 1e). Upon DNA damage, the tumor suppressor
protein TP53 (hereafter referred to as p53) is rapidly induced and
mediates multiple responses, including DNA repair, cell cycle
arrest, apoptosis, and senescence27. Furthermore, reduction of
homologous recombination activity and of RAD51 has been
shown to result in increased p5328. Thus, we hypothesized that
reduction of BMPR2 could induce p53. As expected, si-BMPR2-
transfected pulmonary microvascular endothelial cells showed an
~36% increase in p53 protein compared to control siRNA-
transfected cells (P= 0.0010, Fig. 1f), which is similar to the
increase observed in endothelial cells from the endothelial
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Fig. 2 DNA damage leads to a depletion of BMPR2 and RAD51. a Pulmonary microvascular endothelial cells (PMVECs) were treated with DNA damaging
agent mitomycin C (MMC) or vehicle (H2O, Con) for 14 h followed by qRT-PCR analysis of BMPR2, BRCA1, and RAD51 mRNA relative to GAPDH mRNA
(n= 3). b PMVECs were treated with MMC or vehicle (H2O, Con) for 14 h or 24 h, followed by immunoblot analysis of RAD51, BMPR2, and GAPDH
(loading control). Representative image and the quantitation of three independent experiments are shown (n= 3). c RAD51, BMPR2, and GAPDH (loading
control) protein amount in PMVECs treated with vehicle (H2O, Con) or MMC with or without proteasome inhibitor MG-132 were analyzed by immunoblot.
Representative image and the quantitation of three independent experiments are shown (n= 3). Bars represent mean ± SEM from three different
experiments per conditions in (a–c). *P < 0.05, **P < 0.01, and ***P < 0.001 versus respective control. Unpaired two-tail t-test was used in (a, b). One-way
ANOVA followed by Tukey’s multiple comparisons test was used in (c)
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cell-specific BMPR2 knockout mouse29. Consistent with the
induction of p53, p21 mRNA, a transcriptional target of p53, was
induced fourfold in si-BMPR2 cells compared to control (P=
0.047, Fig. 1g). These results demonstrate that loss of expression
of BMPR2 by siRNA leads to the depletion of RAD51 and
accumulation of DNA damage in pulmonary microvascular
endothelial cells.
DNA damaging agents lead to RAD51 deficiency. We pre-
viously showed that the treatment of pulmonary microvascular
endothelial cells with DNA damaging chemotherapy agents, such
as mitomycin C, induces a rapid reduction of BMPR2 and
BRCA123. When pulmonary microvascular endothelial cells were
treated with mitomycin C (50 µg/mL) for 14 h, BMPR2, BRCA1,
and RAD51 mRNAs were reduced to 71% (P= 0.013, Fig. 2a),
67% (P= 0.0002, Fig. 2a), and 38% (P= 0.0157, Fig. 2a),
respectively, when compared to control cells. Concurrently, the
amount of BMPR2 and RAD51 proteins was reduced by 64 and
62%, respectively (P= 0.0004 and P= 0.0365, Fig. 2b, 14 h). A
similar reduction of BMPR2 and RAD51 proteins was observed
after 24 h of mitomycin C treatment (P= 0.0075 and P= 0.0002,
Fig. 2b, 24 h) and 6 h of camptothecin treatment (P= 0.0004 and
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P= 0.0331, Supplementary Fig. 1). Conversely, when pulmonary
microvascular endothelial cells were treated with the proteasome
inhibitor MG-132 to prevent the degradation of BMPR2 protein
induced by mitomycin C (P < 0.05, Fig. 2c), RAD51 protein was
increased 1.7-fold (P < 0.05, Fig. 2c). These results support the
hypothesis that DNA damage agent-induced RAD51 deficiency in
pulmonary microvascular endothelial cells might be caused
indirectly by downregulation of BMPR2.
RAD51 deficiency promotes DNA damage. Next, we performed
alkaline comet assay to compare the sensitivity of pulmonary
microvascular endothelial cells to DNA damage agents in the
presence or absence of BMPR2. After mitomycin C treatment, the
amount of RAD51 protein in si-BMPR2-treated cells was 28%
lower than in control siRNA-treated cells (P < 0.05, Fig. 3a). We
observed a concomitant 22.6% increase of DNA damage in si-
BMPR2 cells compared to control cells upon mitomycin C
treatment (P < 0.001, Fig. 3b). A similar result was obtained fol-
lowing treatment with camptothecin, a different DNA damaging
agent, upon which the extent of DNA damage measured by
alkaline comet assay was 14% higher in si-BMPR2 cells than in
controls (P < 0.0001, Fig. 3c). These results further support the
hypothesis that pulmonary microvascular endothelial cells with
reduced BMPR2 are more susceptible to DNA damaging agents23.
The level of DNA damage in si-BMPR2 cells after camptothecin
treatment was comparable to that borne by cells transfected
with si-RAD51 (23.6%, P < 0.0001, Fig. 3d). Upon downregulation
of RAD51 mRNA (P= 0.049, Supplementary Fig. 2a) and pro-
tein by siRNA (P= 0.0006, Supplementary Fig. 2b), BMPR2
mRNA and protein (Fig. 3e) were unchanged, suggesting that
BMPR2 is an upstream regulator of RAD51. These results support
a causal relationship between RAD51 deficiency and accumula-
tion of DNA damage in pulmonary microvascular endothelial
cells.
BMP9 treatment rescues RAD51 deficit and DNA damage. A
recent study reported that selective enhancement of endothelial
BMPR2 signaling by BMP9 was able to rescue endothelial cells
from apoptosis and pulmonary arterial hypertension in mice
carrying a heterozygous BMPR2 mutation30. When pulmonary
microvascular endothelial cells were treated with BMP9, cells
were protected from the mitomycin C-mediated decrease in
BMPR2 and RAD51 mRNAs (P < 0.0001 and P < 0.001, Supple-
mentary Fig. 3a) and proteins (P < 0.05, Fig. 4a). Induction by
mitomycin C of γH2AX, a marker of DNA damage, was abol-
ished by co-treatment with BMP9 (P < 0.001, Fig. 4a). Unlike
BMP9 (Fig. 4a), BMP4 was unable to inhibit mitomycin C-
mediated BMPR2 and RAD51 depletion and γH2AX induction
(Supplementary Fig. 3b). Consistently, the relative amount of
phospho-SMAD1/5/8 in pulmonary microvascular endothelial
cells stimulated with 10 ng/mL BMP4 was ~42% lower than in
cells stimulated with 10 ng/mL BMP9, indicating that BMP4 is
less potent than BMP9 on endothelial cells (P < 0.05 and P <
0.001, Supplementary Fig. 3c). When pulmonary microvascular
endothelial cells were treated with a small molecule inhibitor of
bone morphogenetic protein signaling, LDN19318931, the
depletion of BMPR2 and RAD51 by mitomycin C was no longer
rescued by BMP9 stimulation (Fig. 4b). Concurrently, the mito-
mycin C-mediated induction of DNA damage (γH2AX) was no
longer rescued by BMP9 (Fig. 4b). These results suggest that the
BMP signaling pathway, inhibited by LDN193189, plays a role in
the rescue of RAD51 and DNA damage by BMP9. Furthermore,
when pulmonary microvascular endothelial cells were treated
with a low concentration of LDN193189 for 72 h, which inhibited
the BMP9–BMPR2–SMAD signaling axis based on the suppres-
sion of the bone morphogenetic protein targets ID1 and
ID3 mRNAs (P= 0.0079 and P= 0.048, Supplementary Fig. 4)32,
RAD51 protein was reduced by ~47% (P= 0.0253, Fig. 4c), and
DNA damage was increased by 43%, as measured by alkaline
comet assay (P < 0.0001, Fig. 4d). Similarly, both the chemical
inhibition of the endothelial-specific type I BMP receptor ALK-1
(also known as ACVRL1) by K0228833, confirmed by ~40%
reduction of SMAD1/5/8 phosphorylation (P= 0.0006, Supple-
mentary Fig. 5a), and the knockdown of ALK-1 by siRNA (P=
0.0004, Supplementary Fig. 5b) in pulmonary microvascular
endothelial cells resulted in a reduction of RAD51 protein by
~31% (P= 0.0056, Supplementary Fig. 5a) and 42% (P= 0.0376,
Supplementary Fig. 5b), respectively. Finally, the depletion of the
signal transducers SMAD1 and SMAD5 (P= 0.0005 and P=
0.0084, Supplementary Fig. 5c) led to a small reduction of RAD51
(Supplementary Fig. 5c). Altogether, these results support a cri-
tical role of the BMP9–ALK-1–BMPR2 signaling axis in the
maintenance of RAD51 and the protection of genome integrity in
pulmonary microvascular endothelial cells.
Downregulation of the microRNA-96–RAD51 axis by BMP
signaling. We previously showed that a small noncoding
microRNA-96 (miR-96) expression is repressed upon stimulation
of the bone morphogenetic protein signaling pathway in pul-
monary artery smooth muscle cells34. miR-96 targets the RAD51
mRNA and reduces its expression35. We hypothesized that the
BMP9–ALK-1/BMPR2–SMAD axis is responsible for the
decrease of miR-96 also in pulmonary microvascular endothelial
cells, thus allowing RAD51 to be expressed. When BMPR2 was
inhibited by si-BMPR2, the amount of miR-96 was increased 2-
fold (P= 0.0322, Fig. 5a), as also measured in pulmonary artery
smooth muscle cells34. miR-21, whose expression is induced by
the BMP-SMAD pathway36, was decreased by 41.4% upon inhi-
bition of BMPR2 by si-BMPR2 (P= 0.0140, Fig. 5a). When
Fig. 3 Maintenance of RAD51 and genome integrity is controlled by BMPR2 signaling pathway. Pulmonary microvascular endothelial cells (PMVECs) were
transfected with Control (Con), BMPR2, or RAD51 siRNAs. After 24 h, PMVECs were treated with mitomycin C (MMC) for 14 h or camptothecin (CPT) for
6 h. a The amount of RAD51 protein normalized to GAPDH was measured in PMVECs transfected with Con or BMPR2 siRNAs and treated with MMC or
vehicle (H2O, Con) for 14 h. Representative image and the quantitation of three independent experiments are shown (n= 3). b Single-cell gel
electrophoresis (alkaline comet assay) was performed using Con or BMPR2 siRNA-transfected PMVECs after vehicle (Con) or MMC treatment for 14 h and
the fraction (%) of cells with DNA damage was quantitated by ImageJ software. Representative images of alkaline comet assay and the quantitation of
60–70 cells are shown. c Alkaline comet assay was performed using Con or BMPR2 siRNA-transfected PMVECs after vehicle (DMSO, Con) or CPT
treatment for 6 h and the degree of DNA damage in cells was examined. Representative images and the quantitation of 70–100 cells are shown. d Alkaline
comet assay was performed using Con or RAD51 siRNA-transfected PMVECs after vehicle (Con) or CPT treatment for 6 h and the degree of DNA damaged
cells was compared (n= 100–160). e Con or RAD51 siRNA was transfected in PMVECs, followed by quantitation of BMPR2mRNA and BMPR2 protein (n=
3). GAPDH was used for normalization. Bars represent mean ± SEM from three different experiments per conditions in (a–e). *P < 0.05, **P < 0.01, ***P <
0.001, and ****P < 0.0001 versus a respective control. One-way ANOVA followed by Tukey’s multiple comparisons test was used in (a–d). Unpaired two-
tail t-test was used in (e)
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pulmonary microvascular endothelial cells were treated with
LDN193189 and the bone morphogenetic protein signaling
pathway was attenuated (P= 0.0079 and P= 0.048, Supplemen-
tary Fig. 4), miR-96 level increased by 54% (P= 0.0327, Fig. 5b).
Similarly, when ALK-1 was reduced by siRNA (P= 0.004, Sup-
plementary Fig. 6a), miR-96 increased by ~23% (P= 0.0488,
Supplementary Fig. 6a). Inactivation of miR-96 by transfection of
antisense oligonucleotides (anti-miR-96, P= 0.01, Supplementary
Fig. 6b) prevented the reduction of RAD51 mRNA (P < 0.01,
Supplementary Fig. 6c) and protein (P < 0.05, Fig. 5c) by si-
BMPR2 (P < 0.01 Supplementary Fig. 6c and P < 0.05, Fig. 5c).
Conversely, exogenous expression of miR-96 (P= 0.05, Supple-
mentary Fig. 6d) led to ~54% reduction of RAD51 protein (P=
0.0078, Fig. 5d) and increased the amount of DNA damage in
RAD51
GAPDH
γH2AX
Con MMC Con MMC
LDN – – + +
– – + +BMP9
37 kDa
37 kDa
17 kDa
BMPR2 130 kDa
GAPDH
RAD51
Con LDN
37 kDa
37 kDa
MMC
γH2AX
GAPDH
RAD51
BMP9 – – + +
MMCCon Con
37  kDa
17 kDa
37 kDa
130 kDaBMPR2
2.5
2.0
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
1.5
1.0
0.5
0.0
2.0
1.5
1.0
0.5
0.0
Con Con
BMP9 – – + +BMP9 – – + +BMP9 – – + +
MMC MMCCon ConMMC MMCCon ConMMC MMC
RAD51 protein BMPR2 protein
********** *
γH2AX protein
1.5
1.0
0.5
0.0
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
3
2
1
0
2.0
1.5
1.0
0.5
0.0
BMP9
LDN
–
– –
– +
+
+– – + +
+LDN – – + +
BMP9– – + +
LDN – – + +
BMP9
Con ConMMC MMCCon ConMMC MMC Con ConMMC MMC
RAD51 protein BMPR2 protein
**
**
γH2AX protein
*
* * *
2.5
2.0
1.5
1.0
0.5
0.0
Fo
ld
 c
ha
ng
e
*
*
2.0
1.5
1.0
0.5
0.0
RAD51 protein
*
Con LDN
a
b
Control
Ta
il 
D
N
A 
%
100
80
60
40
20
0
****
Con LDN
LDN193189
dc
Fig. 4 Activation of BMPR2 signaling by BMP9 partially rescues RAD51 and reduces sensitivity to DNA damage agent. a Pulmonary microvascular
endothelial cells (PMVECs) were treated with vehicle (Con, H2O) or mitomycin C (MMC) with or without BMP9 (10 ng/mL) for 14 h. RAD51 and BMPR2
protein relative to GAPDH were examined by immunoblot. γH2AX was studied to measure the amount of double-strand breaks. Representative image and
the quantitation of six independent experiments (n= 6) are shown. b RAD51 and BMPR2 protein amount in PMVECs treated with vehicle (H2O, Con) or
MMC with or without bone morphogenetic protein receptor kinase inhibitor LDN193189 (LDN; 100 nM) in combination with BMP9 for 14 h were examined
by immunoblot and the quantitation of three independent experiments are shown (n= 3). γH2AX represents the amount of double-strand breaks. GAPDH
was used for normalization. c RAD51 and GAPDH (loading control) protein amount in PMVECs treated with or without LDN193189 (100 nM) for 72 h.
Representative image and the quantitation of three independent experiments are shown (n= 3). d PMVECs were treated with or without LDN193189 (100
nM) for 72 h, and the amount of DNA damage was measured by single-cell gel electrophoresis (alkaline comet assay). The percentage of cells with DNA
damage was analyzed using ImageJ software. Representative images of alkaline comet assay and the quantitation of 136–162 cells are shown. Bars
represent mean ± SEM from six different experiments per conditions in (a) and from three different experiments per conditions in (b–d). *P < 0.05, **P <
0.01, ***P < 0.001, and ****P < 0.0001 versus respective control. One-way ANOVA followed by Tukey’s multiple comparisons test was used in (a, b).
Unpaired two-tail t-test was used in (c, d)
COMMUNICATIONS BIOLOGY | DOI: 10.1038/s42003-018-0152-1 ARTICLE
COMMUNICATIONS BIOLOGY |  (2018) 1:149 | DOI: 10.1038/s42003-018-0152-1 | www.nature.com/commsbio 7
– – + +
37 kDa
130 kDa
37 kDa
d
c
BMPR2
RAD51
GAPDH
siRNA
Anti-miR-96
a
RAD51
GAPDH
Con miR-96mimic
37 kDa
37 kDa
e Con mimic miR-96 mimic
b
0.00015 0.00010
0.00008
0.00006
0.00004
0.00002
0.00000
0.3
0.2
0.1
1.0
0.5
0.0
siRNA
Anti-miR-96
mimic Con miR-96 mimic Con miR-96
siRNA
Anti-miR-96– – + + – – + +
0.0
2.0
1.5
1.0
0.5
0.0
*
*
*
* *
*
**
**
****
miR-96 miR-21 miR-96
0.00010
0.00005
0.00000
m
iR
N
A 
(re
lat
ive
 to
 U
6)
m
iR
N
A 
(re
lat
ive
 to
 U
6)
Fo
ld
 c
ha
ng
e
1.0
100
80
60
40
20
0
0.5
0.0
Fo
ld
 c
ha
ng
e
Ta
il 
D
N
A 
%
Fo
ld
 c
ha
ng
e
m
iR
N
A 
(re
lat
ive
 to
 U
6)
siRNA Con BMPR2 siRNA Con ConBMPR2
RAD51 protein
RAD51 protein
BMPR2 protein
Con BMPR2 Con BMPR2Con BMPR2 Con BMPR2
Co
n
BM
PR
2
Co
n
BM
PR
2
LDN
Fig. 5 Increased miR-96 upon depletion of BMPR2 promotes attenuation of RAD51. a Pulmonary microvascular endothelial cells (PMVECs) were
transfected with control (Con) or BMPR2 siRNAs for 48 h, followed by quantitation of miR-96 (n= 5) and miR-21 (n= 3) relative to U6 snRNAmeasured by
quantitative PCR analysis. b PMVECs were treated with vehicle (DMSO, Con) or LDN193189 (LDN; 100 nM) for 72 h followed by quantitation of miR-96
relative to U6 snRNA (n= 3). c RAD51 and BMPR2 protein in PMVECs co-transfected with Con or BMPR2 siRNAs with anti-miR-96 or control anti-miRNA.
d PMVECs were transfected with control mimic (Con) or miR-96 mimic (miR-96) for 48 h, followed by quantitation of RAD51 by immunoblot (n= 3) and
e the amount of DNA damage was measured using alkaline comet assay from 204–235 cells using ImageJ software. Bars represent mean ± SEM from five
different experiments per conditions in (a) (miR-96) and from three different experiments per conditions in (a) (miR-21) and (b–e). *P < 0.05, **P < 0.01,
and ****P < 0.001 versus respective control. Unpaired two-tailed t-test was used in (a, b) and (d–e). One-way ANOVA followed by Tukey’s multiple
comparisons test was used in (c)
ARTICLE COMMUNICATIONS BIOLOGY | DOI: 10.1038/s42003-018-0152-1
8 COMMUNICATIONS BIOLOGY |  (2018) 1:149 | DOI: 10.1038/s42003-018-0152-1 | www.nature.com/commsbio
pulmonary microvascular endothelial cells (P= 0.0001, Fig. 5e).
These results suggest that constitutive suppression of miR-96 by
the BMP9–BMPR2 signaling axis is essential to support the
expression of RAD51 and maintain a sufficient level of DNA
repair in pulmonary microvascular endothelial cells.
Reduction of RAD51 in animal models of pulmonary arterial
hypertension and human patients. To investigate in vivo the
status of RAD51 in the presence of a loss-of-function mutation in
BMPR2, we measured the RAD51 protein by immunoblotting
using whole lung lysates from wild-type mice (+/+) or from
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mutant mice with reduced BMPR2 expression due to a mutation
of arginine 899 into a stop codon in one allele of BMPR2 (R899X/
+)30. Around 6 months of age, R899X/+ mice develop mild
pulmonary arterial hypertension and mimic the genetic back-
ground observed in human pulmonary arterial hypertension
patients30. Interestingly, 6-month-old R899X/+ mice showed a
16% reduction of RAD51 protein compared to control littermates
(+/+) (P= 0.0033, Fig. 6a). To address the species- and cell-type
specificity of this effect, we evaluated whether loss of function of
BMPR2 also results in a decrease of RAD51 in rat pulmonary
artery smooth muscle cells. Indeed, the reduction of RAD51 was
not specific for pulmonary microvascular endothelial cells, as
pulmonary artery smooth muscle cells isolated from rats with the
heterozygous BMPR2 mutation W508X (W508X/+), producing
an early stop codon and an ~47% reduction of BMPR2 protein
(P= 0.0022, Supplementary Fig. 7a)37, showed a 68% decrease in
RAD51 mRNA (P= 0.0395, Supplementary Fig. 7b) and a 74%
decrease in RAD51 protein (P < 0.0004, Fig. 6b) compared to
control rats (+/+). This result suggests that the regulatory link
between BMPR2 and RAD51 can be observed in vivo in different
vascular cell types and rodent species. As R899X/+ mice carry the
heterozygous BMPR2mutation in all tissues, we further examined
whether loss of function of BMPR2 mediates DNA damage in
tissues other than pulmonary vascular cells, such as the liver and
the right ventricle. Interestingly, although we detected an ~2.2-
fold (P= 0.0051, Supplementary Fig. 8a) and an ~1.8-fold (P=
0.0814, Supplementary Fig. 8b) increase in DNA damage in the
liver and the right ventricle of R899X/+ mice, respectively, we did
not find a significant change in the amount of RAD51 protein
(Supplementary Fig. 8a and 8b). This result suggests that RAD51
may play a more critical role in the protection of genome integrity
in response to BMPR2 signaling in pulmonary vascular cells,
while other factors may mediate the effect of BMPR2 on DNA
damage in liver and heart cells.
Finally, we examined whether attenuation of RAD51 could be
observed in a non-genetic model of pulmonary arterial
hypertension, the Sugen–Hypoxia38-treated rats, and in human
patients affected by idiopathic pulmonary arterial hypertension.
The Sugen–Hypoxia treatment consists of exposure to a single
dose of SUGEN-5416, followed by 3 weeks in hypoxia (10% O2)
and additional 5 weeks in normoxia (total of 8 weeks)39. It has
been reported that Sugen–Hypoxia-treated rats exhibit both a
depletion of BMPR2 and elevated DNA damage39,40. Immuno-
histochemical analysis of RAD51 in the lung sections of
Sugen–Hypoxia-treated rats compared to control rats showed
50% reduction (P < 0.0390) of RAD51 in the endothelium,
identified by the endothelial marker von Willebrand Factor
(Fig. 6c). Similarly, immunohistochemistry of lung sections from
idiopathic pulmonary arterial hypertension patients showed 76%
reduction of RAD51 (P= 0.0038) in the endothelium of
pulmonary arteries compared to control samples (Fig. 6d). To
address the kinetics of RAD51 regulation, we measured the
induction of DNA damage in the pulmonary endothelium in the
Sugen–Hypoxia-treated rat model at various time points and
found that the increase in DNA damage was detected as early as
3 days (Fig. 6e) and significantly increased after 1 week (P < 0.01,
Fig. 6e) after Sugen–Hypoxia treatment, suggesting that DNA
damage in the endothelium proceeds vascular remodeling, which
can be detected by 5 weeks (3 weeks in hypoxia plus 2 weeks in
normoxia) (Fig. 6e). The amount of DNA damage was further
increased 5 weeks after the treatment (P < 0.0001, Fig. 6e), and
remained stable until 8 weeks (3 weeks in hypoxia plus 5 weeks in
normoxia), when it could also be detected in other vascular cells
(Fig. 6e). These results suggest that DNA damage correlates with
attenuation of BMPR2 and RAD51 in endothelial cells in rodents
and humans, and it precedes pulmonary vascular remodeling in
induced pulmonary arterial hypertension. At a later stage, the
accumulation of DNA damage in both endothelial cells and other
cells may aggravate the vascular lesions in pulmonary arterial
hypertension (Fig. 7).
Discussion
In this study, we uncovered a role of the bone morphogenetic
protein signaling pathway in maintenance of genome stability
through RAD51 protein, which prevents pathological remodeling.
Bone morphogenetic protein signaling is essential for the reg-
ulation of vascular morphogenesis and function. Mutations that
cause deregulation of bone morphogenetic protein signaling have
been linked to at least two human vascular diseases, pulmonary
arterial hypertension and hereditary hemorrhagic telangiecta-
sia41–43. In particular, bone morphogenetic proteins are required
for the differentiation and the structural and functional integrity
of normal vascular endothelial cells41–43. Bone morphogenetic
proteins exhibit pleiotropic activities through their downstream
effectors, the SMAD proteins, which regulate gene expression by
modulating transcription of both protein coding genes and
noncoding microRNAs (miRNAs)44,45. Here we show that tran-
scriptional suppression of miR-96 by the bone morphogenetic
protein pathway is critical for the expression of RAD51 and the
prevention of DNA damage in pulmonary microvascular endo-
thelial cells (Fig. 7), which in turn are fundamental to the integrity
of the pulmonary vasculature.
It has been reported previously that female R899X/+ mice
(6 months old) express less miR-96 in pulmonary artery smooth
muscle cells than control (+/+) female mice46. Consequently, the
Fig. 6 Attenuation of RAD51 in animal models and human patients of pulmonary arterial hypertension. a RAD51 and α-tubulin (loading control) protein
amount was measured in whole lung lysates from 6-month-old BMPR2 R899Xmutant mice (R899X/+) or littermate controls (+/+). Representative image
of the blot and the quantitation of four individual samples are shown (n= 4). b RAD51 protein amount in pulmonary arterial smooth muscle cells isolated
from control rats (+/+) or rats with heterozygous BMPR2 W508X mutation (W508X/+) were examined. Representative image of immunoblot and the
quantitation of four independent experiments are shown (n= 4). c Representative images of immunohistochemistry of RAD51 and von Willebrand factor
(vWF), a marker for endothelial cells, in lungs isolated from male control and SUGEN-5416/chronic hypoxia (SU/H)-treated rats (n= 3). Arrows indicate
the endothelium of pulmonary arteries. Scale bars indicate 25 μm. d Representative images of hematoxylin and eosin (H&E) and immunohistochemical
staining for RAD51 (200×), vWF, and α-smooth muscle actin (αSMA), a marker for smooth muscle cells, in lungs isolated from a control individual and an
idiopathic pulmonary arterial hypertension patient (IPAH) (n= 4). Asterisks and arrows indicate the location of pulmonary arteries, pulmonary
endothelium, and pulmonary artery smooth muscle cells, respectively. Scale bars indicate 100 μm. e Representative images of immunofluorescence
staining of DNA damage marker γH2AX (red), endothelial marker, vWF (green), and DAPI in lungs from control (Con) and SU/H-treated rats (n= 3).
Schematic diagram of SU/H treatment and different time points of sampling lungs are indicated. The relative amount of γH2AX signal in the endothelium
was quantitated. Scale bar indicate 50 μm. Bars represent mean ± SEM from four different experiments per conditions in (a, b), and (d), and from three
different experiments per conditions in (c) and (e). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 versus respective control. Unpaired two-tail t-test
was used in (a–d). One-way ANOVA followed by Tukey’s multiple comparisons test was used in (e)
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increased 5-hydroxytriptamine 1B receptor and serotonin med-
iate proliferation of pulmonary artery smooth muscle cells and
promote pulmonary vascular remodeling in female R899X/+
mice46. Unlike female R899X/+ mice, male R899X/+ mice
express the same amount of miR-96 as +/+ mice, for unknown
reasons46. It is unclear why miR-96 is decreased in pulmonary
artery smooth muscle cells from R899X/+ female mice, while
knockdown of BMPR2 or inhibition of bone morphogenetic
protein signaling in pulmonary microvascular endothelial cells
increases miR-96. We speculate that the discrepancy is, in part,
due to a cell-type-specific response of pulmonary artery smooth
muscle cells vs microvascular endothelial cells. It is also plausible
that the genetic perturbation of the bone morphogenetic protein
pathway in mice triggers a compensatory gene regulatory network
that adapts to BMPR2 haploinsufficiency, while the acute per-
turbation of the bone morphogenetic protein pathway would not
allow sufficient time for genetic compensation47.
The inhibition of miR-96 has also been shown to be critical in
the context of the pathogenesis of Alzheimer’s disease, according
to a study performed in brain microvascular endothelial cells in
response to granulocyte-macrophage colony-stimulating factor48.
Furthermore, miR-96-mediated downregulation of RAD51 in
cancer cell lines increases their sensitivity to chemotherapy agents
and leads to cell death35, a result similar to our observations in
pulmonary microvascular endothelial cells upon inhibition of
bone morphogenetic protein signaling. Thus, we speculate that
the suppression of miR-96 to boost RAD51 expression by the
bone morphogenetic protein–SMAD pathway may operate not
only in pulmonary microvascular endothelial cells, but also in
other cell types, whereby bone morphogenetic protein signaling
would play a prevalent role as a guardian of genome integrity.
Furthermore, miR-96 expression in peripheral blood mono-
nuclear cells has been reported to increase upon aging49, sug-
gesting that BMPR2 mutation carriers may experience a further
age-dependent reduction of RAD51, which may correlate with
pulmonary arterial hypertension progress with age. Finally, miR-
96 has been classified as an oncogenic miRNA because its over-
expression has been found in various tumors50. It is unknown
whether miR-96 expression in tumors correlates with the extent
of DNA damage. In addition to miR-96-RAD51-dependent reg-
ulation, it has been reported that the miR-223–poly (ADP-ribose)
polymerase 1 axis also plays an important role in DNA damage
control51. In pulmonary artery smooth muscle cells from human
and animal models of pulmonary arterial hypertension, miR-223
is reduced, which promotes activation of poly (ADP-ribose)
polymerase 1 and DNA damage, downregulation of miR-204, and
the subsequent activation of transcription factors (nuclear factor
of activated T cells and hypoxia-inducible factor 1-α), leading to
aberrant proliferation of pulmonary artery smooth muscle
cells40,52. It is plausible that the therapeutic delivery of exogenous
miR-223 and/or miR-204 might ameliorate or prevent the
development of vascular remodeling in pulmonary arterial
hypertension, although efficient conveyance of miRNAs to pul-
monary artery smooth muscle cells might be more challenging
than to vascular endothelial cells.
Dysfunctions of BMPR2 have been associated with a hypoxic
microenvironment53,54 and a metabolic switch from mitochon-
drial glucose oxidation to cytoplasmic glycolysis55. This metabolic
change is followed by increased production of intracellular
reactive oxygen species, such as superoxide and hydrogen per-
oxide, resulting in formation of oxidative DNA damage23,55,56.
Under physiological conditions, levels of reactive oxygen species
are kept in balance to prevent their harmful effect to the cells57.
However, sustained increase of intracellular reactive oxygen
species can result in single-strand breaks that are readily con-
verted to double-strand breaks15. On the other hand, increased
levels of intracellular reactive oxygen species can also indicate a
response to DNA damage58. Both the exogenous DNA damage by
DNA damaging agents and the endogenous DNA damage by
increased production of reactive oxygen species could compro-
mise the cellular DNA repair mechanisms15. Therefore, the
maintenance of an effective DNA repair system is critical to
prevent gene mutations and to further the maintenance of
genomic stability15. An accumulation of mutations and genomic
instability occur when specific cell cycle checkpoint pathways or
DNA damage response components, such as RAD51, are
deregulated, or when the damage-load overcomes the ability of
the cells to restore the damage15. Interestingly, both pulmonary
artery smooth muscle cells and endothelial cells in which BMPR2
is depleted show smaller mitochondria and are less variable in
size than healthy cells29,59. Similarly, the downregulation of
RAD51 is associated with a hypoxic environment60 and RAD51-
depleted cells show a decreased size and a smaller number of
mitochondria61, which leads to mitochondrial dysfunctions, such
as decreased mitochondrial membrane potential and adenosine
triphosphate production, and increased DNA degradation61. It
has been previously reported that the reduction of BMPR2 in
endothelial cells promotes abnormal mitochondria function and
mitochondrial DNA damage, which results in endothelial cell
apoptosis29. The deregulation of DNA damage response
mechanism through the BRCA1–RAD51 axis by reduced BMPR2,
followed by an increased amount of DNA damage, could at least
in part explain the formation of apoptosis-resistant and
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Fig. 7 Schematic diagram of the maintenance of RAD51 by the BMP9–ALK-
1/BMPR2 signaling axis. In healthy individuals, RAD51 is maintained in the
pulmonary endothelium as the BMP9–ALK-1/BMPR2 signaling axis
downregulates miR-96 expression and prevents the destabilization of RAD51
mRNA. When the BMP9–ALK-1/BMPR2 signaling axis is deregulated,
elevation of miR-96 leads to attenuation of RAD51. As a result, DNA
damage accumulates in the pulmonary endothelium over several decades
causing endothelial injury and dysfunction, and eventually triggers
pulmonary vascular remodeling
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hyper-proliferative endothelial cells. Damage to mitochondrial
DNA might also need to be considered, as suggested by the recent
finding that the accumulation of HSP90 in the mitochondria of
pulmonary artery smooth muscle cells in animal models of pul-
monary arterial hypertension is implicated in the maintenance of
mitochondrial DNA integrity62. Although the status of mito-
chondrial DNA damage in pulmonary arterial hypertension
patients with or without BMPR2mutations is currently unknown,
it is plausible to speculate that the BMPR2–RAD51 axis may play
a role in the maintenance of pulmonary vascular homeostasis by
protecting the integrity of not only nuclear DNA but also mito-
chondrial DNA, since RAD51 functions both in the nucleus and
in the mitochondria63.
In a recently published study, human distal pulmonary arteries
and pulmonary artery smooth muscle cells isolated from pul-
monary arterial hypertension patients were shown to have
increased amounts of TP53 binding protein 1 and poly (ADP-
ribose) polymerase 140, which are associated with non-
homologous end-joining64. In contrast to homologous recombi-
nation, non-homologous end-joining rejoins the DNA ends
without DNA template, frequently leaving insertions and dele-
tions at the breakpoint15,65. Furthermore, increased p53 is asso-
ciated with decreased homologous recombination activity and
reduced RAD51 expression and increased non-homologous end-
joining28,64. These observations are consistent with our results, as
reduced BMPR2 results in an increase of p53 both in culture and
in animal models of pulmonary arterial hypertension29, and in
reduced expression of RAD51. Taken together, these results
suggest that endothelial cell dysfunction and cell death can be
initiated by deregulation of homologous recombination through
decreased RAD51 and BRCA1 and a switch to non-homologous
end-joining, an error-prone DNA repair mechanism, leading to
accumulation of DNA errors, mutations, rearrangements, and
even chromosomal translocations, as seen in endothelial cells
from plexiform lesions isolated from pulmonary arterial hyper-
tension patients13,14,66–68. Increased DNA damage is not specific
to pulmonary vasculature, as lymphoblastoid cells and peripheral
blood cells derived from pulmonary arterial hypertension patients
reportedly exhibit increased DNA damage and increased sensi-
tivity to the chemotherapy agents etoposide and bleomycin66.
Both in vitro and in vivo studies have elucidated several
molecular mechanisms by which bone morphogenetic protein
signaling affects vascular endothelial cell homeostasis and its
failure leads to the pathologies of pulmonary arterial hyperten-
sion and hereditary hemorrhagic telangiectasia41,43. Still, it
remains unclear why deregulation of bone morphogenetic protein
signaling would cause vascular remodeling only 30–40 years after
birth, and not earlier. Here we propose that a potential long-term
effect of the decrease of bone morphogenetic protein signaling is
the accumulation of DNA damage and mutations due to RAD51
depletion mediated by miR-96. Reduction of RAD51 is observed
not only in pulmonary microvascular endothelial cells but also in
pulmonary artery smooth muscle cells isolated from rats with
heterozygous BMPR2 mutation and from human idiopathic
pulmonary arterial hypertension patients. The cellular responses
triggered by the downregulation of DNA repair, however, are cell-
type specific. Pulmonary artery smooth muscle cells isolated from
pulmonary arterial hypertension patients exhibit an increased
amount and activation of poly (ADP-ribose) polymerase 1, which
promotes the survival and proliferation of pulmonary artery
smooth muscle cells40, while endothelial cells undergo apoptosis
and endothelial cell dysfunction, as observed in pulmonary
arterial hypertension patients69. In both monocrotaline and
Sugen–Hypoxia-treated rat pulmonary arterial hypertension
models, a 2-week treatment with the poly (ADP-ribose) poly-
merase 1 inhibitor ABT-888 after the establishment of the disease
was able to reverse the pulmonary arterial hypertension pheno-
type40. These preclinical studies have led to a phase I clinical trial
of a clinically approved poly (ADP-ribose) polymerase 1 inhibitor
(olaparib) for the treatment of pulmonary arterial hypertension,
which will be completed in 2019 (https://clinicaltrials.gov/ct2/
show/NCT03251872).
BMP9, but not BMP4, is able to rescue the mitomycin C-
mediated DNA damage in pulmonary microvascular endothelial
cells. BMP9 is a potent ligand in endothelial cells, as it binds with
high affinity to the type I bone morphogenetic protein receptor
ALK-1, which is enriched in endothelial cells, in combination
with BMPR241. On the contrary, BMP4 preferentially binds bone
morphogenetic protein receptor type 1A and bone morphoge-
netic protein receptor type 1B (also known as ALK-3 and ALK-6).
The significance of the BMP9–ALK-1/BMPR2-mediated signal in
endothelial cell is supported by the causal mutations identified in
pulmonary arterial hypertension and hereditary hemorrhagic
telangiectasia patients in the ACVRL1 and GDF2 genes, which
encode ALK-1 and BMP9, respectively70,71. Although rare,
mutations in the ACVRL1 gene were identified in a subset of
pulmonary arterial hypertension patients who also develop her-
editary hemorrhagic telangiectasia72,73. Daily injections of BMP9
into a hereditary pulmonary arterial hypertension model mouse
harboring a heterozygous R899X mutation in BMPR2 ameliorates
the established pulmonary arterial hypertension phenotype,
supporting a therapeutic potential of BMP9 for pulmonary
arterial hypertension30. Our findings pointing to a molecular link
between BMP9 signaling and RAD51 open a new therapeutic
avenue aimed at rescuing the DNA repair enzyme and preventing
DNA damage as a way to halt or delay the development of vas-
cular remodeling in pulmonary arterial hypertension from an
early stage.
Methods
Cell culture. Commercially available human primary pulmonary microvascular
endothelial cells were purchased from ScienCell Research Laboratories (#3000,
Carlsbad, CA) and grown in gelatin-coated dishes on commercial EGM-2 media
(Lonza Clonetics, Fisher Scientific) containing 5% fetal bovine serum (FBS) and
growth factors. Pulmonary microvascular endothelial cells were used between
passages 3 and 8. When noted, endothelial cells were treated with mitomycin C
(50 μg/mL; 14 h) or camptothesin (4 μM; 6 h) (both purchased from Sigma-
Aldrich, St. Louis, MO) to induce DNA damage. H2O or dimethy sulfoxide
(DMSO) was used as a control. To induce BMP signaling, endothelial cells were
treated with BMP9 (10 ng/mL) or BMP4 (10 ng/mL) (R&D Systems, Minneapolis,
MN), or with vehicle for 14 h. To inhibit bone morphogenetic protein signaling,
endothelial cells were treated with LDN193189 (100 nM) or K02288 (1 μM) for
72 h (Cayman Chemical, Ann Arbor, MI). DMSO was used as a control. To pre-
vent protein degradation, MG-132 (100 nM) (Sigma-Aldrich) was used. Rat pul-
monary smooth muscle cells (BMPR2/+(+/+) and BMPR2+/W508X (W508X/+)
PAC1 cells (American Type Culture Correction, Manassas, VA) were grown on
high glucose Dulbecco's modified Eagle's medium (HyCloneTM, GE Healthcare Life
Sciences) with 10% FBS and 1% penicillin–streptomycin. The creation ofW508X/+
PAC1 cells has been previously described37. In brief, BMPR2 mutation (W508X)
was targeted on PAC1 cell line using transcription activator-like (TAL) effector
nucleases (TALEN)-mediated targeted gene mutagenesis. The TAL Effector
Nucleotide Targeter 2.0 (Cornell University, Ithaca, NY) was used to design
TALEN arms. TALEN effectors were transfected to cells together with pcCDN3.1-
eGFP for 48 h, after which eGFP-positive PAC1 cells were sorted using flow
cytometry. After sorting, single cells were seeded into 96-well plate. Mutations
present in each single-cell clone were examined by Sanger sequencing37. All cell
lines used in the study were characterized with cell-specific antibodies and tested
negative for mycoplasma, bacteria, yeast, and fungi.
siRNA transfection. For siRNA transfections, pulmonary microvascular endo-
thelial cells were divided 24 h before transfections. siRNA transfections were done
as previously described23. In brief, a 9.3 μL Lipofectamine RNAiMAX was mixed in
750 μL of Opti-Minimum Essential Medium (Opti-MEM; Gibco, Thermo Scien-
tific, Waltham, MA) and incubated for 5 min at room temperature. Non-targeting
control, BMPR2, BRCA1, RAD51, ACVRL1 (ALK-1), SMAD1, or SMAD5 siRNAs
(all purchased from Dharmacon, Thermo Scientific) were mixed with 750 μL of
Opti-MEM. The final concentration of used siRNA mixture was 100 nM. These
two mixtures were then pooled and incubated for 20 min at room temperature. The
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mixture was added to endothelial cells and incubated at 37 °C for 5 h, after which
5 mL of EGM-2 media containing growth factors was added to the cells. siRNA-
transfected endothelial cells were harvested at 48–72 h after the beginning of
transfections. Knockdown of each gene was determined using quantitative reverse
transcriptase PCR (qRT-PCR) and/or western immunoblotting. For overexpression
of miR-96, pulmonary microvascular endothelial cells were transfected with control
or miR-96 mimics with methods similar to those described for siRNA experiments.
For miR-96 inhibition, pulmonary microvascular endothelial cells were co-
transfected with control or BMPR2 siRNAs together with control anti-miR or anti-
miR-96, with miRNA final concentration of 30 nM. The overexpression and
inhibition of miR-96 was determined using Taqman® microRNA Assay kit for
miR-96 (Thermo Fisher Scientific), as instructed by the manufacturer.
Gene expression analysis. RNA isolation was done using the Qiagen RNeasy®
Mini Kit (Qiagen GmbH, Hilden, Germany) and further reverse transcribed using
iScript cDNA Synthesis Kit (BioRad Laboratories Inc., Hercules, CA) as instructed
by the manufacturer. Quantitative PCR analysis was performed using PerfeCTa®
SYBR Green FastMix® (Quantabio, Beverly, MA) with a BioRad CFX ConnectTM
Real-Time system (BioRad Laboratories Inc.). Primer sets were purchased from
Integrated DNA Technologies (IDT, Coralville, IA). Studied mRNA expression
levels were normalized for GAPDH mRNA expression. For miR-21 and miR-96
expression analysis, the Taqman® microRNA Assay kit (Thermo Fisher Scientific)
was used following the protocol provided by the manufacturer. miR-21 and miR-96
expression levels were normalized against U6 small nuclear RNA (snRNA)
expression. Primers used in the study are summarized in Supplementary Table 1.
Immunoblotting. Whole cell protein extracts were prepared by adding boiling lysis
buffer (10 mM Tris-HCl, 1% SDS, 0.2 mM phenylmethylsulfonyl fluoride)
including protease and phosphatase inhibitors (Sigma-Aldrich, St Louis, MO) to
the cells. Whole tissue protein lysates were prepared by adding boiling lysis buffer,
containing protease and phosphatase inhibitors, directly to the tissues, followed by
quick homogenization. Both whole cell and tissue lysates were then boiled for
10 min, centrifuged for 35 min, and the supernatants were collected into new tubes.
Whole tissue lysates were further centrifuged for 20 min and supernatants were
collected into new tubes. All samples were stored at −80 °C. Protein concentrations
were measured using NanoDrop 2000c (Thermo Scientific). Equal amounts of
protein were loaded onto the wells of Mini-Protean TGXTM 4–15% gels (BioRad
Laboratories), and subjected to electrophoresis under reducing conditions. Gels
were blotted to nitrocellulose membranes (Millipore, Billerica, MA), which were
blocked with 3% bovine serum albumin–1× Tris-buffered saline (TBS) buffer for
1 h at room temperature. Primary antibodies polyclonal rabbit anti-BMPR2
(1:5000; Proteintech, Rosemont, IL #19087-1-AP), monoclonal mouse anti-BMPR2
(1:250, BD Biosciences, San Jose, CA, #612292), monoclonal rabbit anti-RAD51
(46B10) (1:1000; Cell Signaling, Danvers, MA #8875), monoclonal rabbit anti-
RAD51 [EPR4030(3) (1:5000–9000; Abcam, Burlingame, CA, #ab133534), mono-
clonal mouse anti-phospho-Histone H2A.X (Ser139), clone JBW301 (1:1000;
Millipore, #05-636), polyclonal rabbit anti-p53 (1:500, Cell Signaling, #9282 S),
polyclonal rabbit anti-phospho-SMAD1 (Ser463/465)/SMAD5 (Ser463/465)/
SMAD9 (Ser465/467) (1:1000, Cell Signaling, #9511), monoclonal mouse anti-
SMAD1 (1:1000; Bio Matrix Research. Inc. Noda-shi, Chiba, Japan, #BMR00479),
polyclonal rabbit anti-SMAD5 (1:1000, Cell Signaling, #9517), monoclonal mouse
GAPDH (1:3000, Millipore, #MAB374), and α-tubulin (clone DM1A, Sigma-
Aldrich) were incubated overnight at 4 °C. Before adding secondary horseradish
peroxidase-conjugated anti-mouse or anti-rabbit antibodies (1:1000; Cell Signaling,
#7074 and #7076, respectively), membranes were washed with 1× TBS or 1× TBST
(TBS with Tween-20) buffer. Protein visualization was performed using ECL
(Super Signal West Dura, Extended Duration Substrate, Thermo Scientific,
#34076). Densitometry was performed to quantify protein amount per sample
using ImageJ software (NIH, Bethesda, MD). Normalization was performed against
GAPDH protein, and once with α-tubulin.
Alkaline comet assay. Alkaline comet assay kit was purchased from Trevigen
(Trevigen Inc., Gaithersburg, MD) and assay was done following the protocol
provided by the manufacturer. In brief, pulmonary microvascular endothelial cells
transfected with si-Control, si-BMPR2, or si-RAD51, treated with or without
mitomycin C (50 µg/mL; 14 h) or camptothecin (4 µM; 6 h), or pulmonary
microvascular endothelial cells treated with LDN193189 (100 nM) for 72 h, or with
miR-96 mimics were washed once with ice-cold 1× phosphate-buffered saline
(PBS), de-attached, and briefly centrifuged, before being suspended at 2 × 105 cells/
mL in ice-cold 1× PBS. A 50 µL cell suspension was combined with 500 µL
LMAgarose, spread onto CometSlideTM, and placed at 4 °C in the dark for 10 min.
Slides were immersed in Lysis Solution for 60 min at room temperature. Next slides
were immersed in Alkaline Unwinding Solution at room temperature for 30 min
in the dark. Electrophoresis was performed in Alkaline Electrophoresis Solution
(1 V/cm, 300 mA) for 35 min at 4 °C. Slides were immersed in dH2O twice for
5 min and then in 70% ethanol for 5 min in the dark at room temperature. Samples
were dried at 37 °C for 10–15 min before staining with diluted SYBR® Gold for
30 min. Slides were viewed using upright laser scanning confocal Microscope
(LEICA SPE, Buffalo Grove, IL) and the percentage (%) of cells with DNA damage
was analyzed by ImageJ software.
Animal studies. All of the procedures in this study involving vertebrate animals
are contained in protocols that have been reviewed by the Institutional Animal
Care and Use committee at the University of California, San Francisco (UCSF).
The study was performed according to the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institute of Health. All
animals in this study were handled according to institutional animal care and use
committee protocols approved by the Committee on the Ethics of Animal
Experiments of UCSF and the UK Animals (Scientific Procedures) Act 1986 proved
by Home Office Project License 80/2460. For all animal works, determination of
group sizes and randomization was done as previously reported30. In brief,
determination of animal group sizes was done using variance estimation and
minimum detectable differences between each group, as previously done based on
past experience with pulmonary arterial hypertension rodent models30. To perform
studies in an unbiased manner74, randomization was done using an assigned
identification number in each animal, which allowed blinded cardiopulmonary
phenotypic procedures, as previously reported30.
Animal models of pulmonary arterial hypertension
BMPR2+/R889X mice. Creation, phenotyping, and sample preparation of BMPR2-
+/R889X mice has been previously described30. Mice used in the study were all
6 months old with C57Bl/6 background and both male and female mice were
studied. BMPR2+/R889X mice, which showed significantly reduced BMPR230,
develop an age-related pulmonary arterial hypertension, which was confirmed by
measuring right and left ventricular pressures and volumes with Millar PVR-1045
catheter (Millar Instruments, Houston, TX) and by determining right ventricular
hypertrophy using the ratio of right ventricular to left ventricular and septal weight
as previously described30. BMPR2+/+ littermates were used as a control.
Sugen–Hypoxia rat model. Treatment and characterization of rats with SUGEN-
5416–hypoxia-induced pulmonary arterial hypertension has been previously
described30. Lung tissue sample preparation was done as previously described30. In
brief, male Sprague-Dawley rats (150–200 g, Charles River, UK) were randomly
selected to five groups and given a single SUGEN-5416 injection (20 mg per kg,
Tocris, Bristol, UK) in a vehicle containing 0.5% carboxyl methylcellulose sodium,
0.4% polysorbate 80, 0.9% benzyl alcohol (Sigma-Aldrich). Rats in group 1 were
then placed into a 10% O2 chamber and kept in hypoxia for 3 days, removed to
normoxia, and killed the following day. Rats in group 2 were placed into a 10% O2
chamber for 1 week following normoxia and were killed the following day. Rats in
group 3 were placed in hypoxic environment for 3 weeks following the normoxia
for further 2 weeks before they were killed. The group 4 rats were placed on
hypoxic environment for 3 weeks and kept in normoxia for further 5 weeks to
develop pulmonary arterial hypertension. The group 5 rats were used as a control
and were given a vehicle (0.5% carboxyl methylcellulose sodium, 0.4% polysorbate
80, 0.9% benzyl alcohol, Sigma-Aldrich). At the each time-point, rats were assessed
for cardiopulmonary function and killed as previously described30,74.
Human tissue samples. Human lung tissues were obtained from informed and
consenting patients undergoing lung transplantation for end-stage pulmonary
arterial hypertension at Royal Papworth Hospital NHS Foundation Trust. Control
tissues were obtained from patients undergoing lobectomy or pneumonectomy for
lung cancer with tissue being taken from an uninvolved tumor-free region (08/
H0304/56+5).
Immunohistochemistry. Staining of lung sections from normoxia and
Sugen–Hypoxia-treated rats for RAD51 detection were performed using the Vector
Elite ABC kit (Vector Laboratories, Burlingame, CA) following the manufacturer’s
protocol with a rabbit monoclonal RAD51 (EPR4030(3)) (1:200, ab133534,
Abcam) and rabbit polyclonal von Willebrand factor (1:100, ab9378, Abcam)
antibody. Standard protocol for immunohistochemistry for fluorescence staining
was used for γH2AX and von Willebrand factor detection. In brief, sections were
deparaffinized with xylene and rehydrated with graded alcohol series followed by
heat-induced antigen retrieval using Tris-EDTA buffer (pH 9.0). Quenching of
endogenous peroxidase activity was done using 3% H2O2. Sections were stained
using monoclonal mouse anti-phospho-Histone H2A.X (Ser139), clone JBW301
(1:200, Millipore), and rabbit polyclonal von Willebrand factor (1:100, ab9378,
Abcam) antibody with overnight incubation at 4 °C. Sections were labeled using
secondary antibodies goat anti-mouse IgG, Alexa Fluor plus 555, and goat anti-
rabbit IgG, Alexa Fluor 488 (1:250, Thermo Scientific). Lung sections for immu-
nofluorescence were imaged using upright laser scanning confocal microscope
Zeiss LSM 780 NLO FLIM with 63× objective and the number of γH2AX-positive
endothelial cells were quantitated using ImageJ software (NIH). For human sam-
ples, the lung tissue sections were immunostained using a rabbit monoclonal
RAD51 (EPR4030(3)) (1:200, Abcam), rabbit polyclonal von Willebrand factor
(1:100), and monoclonal mouse anti-mouse/rat/human smooth muscle α-actin
(1:100, clone 1A4, Dako, Glostrup, Denmark), labeled using a dextran polymer
conjugated secondary antibody, visualized with 3,3’-diaminobenzidine to create a
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brown reaction product, and counterstained with hematoxylin (all from Dako-
Cytomation, UK). Pulmonary vessels were imaged with light microscope and were
quantified and normalized using ImageJ software (NIH).
Hematoxylin and eosin staining. The hematoxylin and eosin staining was per-
formed following standard procedures75. In brief, sections were deparaffinized with
xylene and rehydrated with graded alcohol series. Sections were stained with Harris
hematoxylin solution followed by counterstain with eosin solution. Sections were
dehydrated through graded alcohol series, cleared with xylene, and mounted with
xylene-based mounting medium.
Statistical analysis. Values from multiple experiments are as mean ± SEM. Each
individual experiment was repeated at least three times. In all statistical analyses, a
normal distribution between samples were assumed. When only two groups were
compared, statistical significance was determined using unpaired two-tailed t-test
and when more than two groups were compared, statistical significance was
determined using one-way analysis of variance (ANOVA) followed by Tukey’s
multiple comparisons test with 95% confidence interval. A P < 0.05 was considered
as significant. Prism GraphPad 6 (La Jolla, CA) was used for statistical analyses.
The number of samples or animals in each group are indicated in the figure
legends.
Data availability
All data generated during this study are included in this published article and its
Supplementary Information files.
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